Why Goldman Sachs Sees Sports Business Booming in Asia
Today's top stories
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
20 minutes ago
- Associated Press
China retaliates against EU with a ban on European medical devices
BANGKOK (AP) — China said Sunday that European medical device companies will be barred from selling to the Chinese government as a countermeasure for the European Union's restrictions on the sale of similar products from China. European companies will be excluded if the budget for procurement is above 45 million yuan ($6.28 million), according to a notice from the Finance Ministry on Sunday with the restrictions in place the same day. The move will not apply to European companies that have invested in China and that manufacture goods in the country. China on Friday imposed anti-dumping duties on European brandy, most notably cognac produced in France. While the duties on brandy include several exceptions for major brandy producers, China and the EU have multiple trade disputes across a range of industries. China protested after many European countries levied duties on EVs made in China. Since then, China has also launched investigations into European pork and dairy products. In June, the EU announced that Chinese companies were to be excluded from any government purchases of more than 5 million euros ($5.89 million). The measure seeks to incentivise China to cease its discrimination against EU firms, the EU said, accusing China of erecting 'significant and recurring legal and administrative barriers to its procurement market.' In response, China has said it had 'no choice but to implement countermeasures.' 'China has repeatedly expressed through bilateral dialogues that it is willing to properly handle differences with the EU through dialogue and consultation and bilateral government procurement arrangements,' said a statement from a spokesman with the Ministry of Commerce. 'Unfortunately, the EU has ignored China's goodwill and sincerity and still insisted on taking restrictive measures and building new protectionist barriers.'
Yahoo
24 minutes ago
- Yahoo
'Gamble worth taking' - but Celtic need 'proven talent'
We asked for your views on the signing of Hayato Inamura after the Japanese centre-back joined Celtic on a four-year contract. Here's what some of you had to say: Kevin: He should be a great improvement on the combined efforts of Liam Scales and Auston Trusty. Advertisement Hugh: Based on his playing record, this signing is either a masterstroke by our scouting and recruitment team or an act of sheer folly - time will tell. Either way for £250,000 it is probably a risk worth taking. Key to it all will be how much game time he will be given? John: Was hoping to sign a better known centre-half but will see how he turns out. Signing him from a team that's near bottom of the J League, doubt he's used to our standard. Ray: Four-year deal for a reason - to make money on him if it works out like many others. Won't be a first-team pick initially but will be tested to see if he has physical presence at the back, which is an Achilles heel clearly shown last season. Bit of a gamble but worth taking. Most of our Japanese players have delivered to date. Alec: All we hear is about 'the model' and it's hard to comment on players when you have not seen them play or they play at a lower standard. However, we need proven talent through the door, not projects. The squad is beginning to look bare and untested with little sign of it being strengthened. John: Could be a decent signing for the money paid, hopefully a step up from error-prone Trusty, who doesn't fill me with confidence any time he plays.
Yahoo
24 minutes ago
- Yahoo
Nissan considers Foxconn EV output to save Oppama from closure, Nikkei says
TOKYO (Reuters) -Nissan Motor is in discussions with Taiwan's Foxconn about a collaboration in electric vehicles that could save its Oppama plant in Japan from closure, the Nikkei business daily reported on Sunday, citing an unidentified Nissan source. Nissan's Oppama plant, which employs about 3,900 workers, has been a potential consolidation target in the struggling Japanese carmaker's restructuring plans, but the floated idea of producing Foxconn-brand EVs at its idle assembly lines could preserve the jobs and supplier networks, Nikkei said. Sign in to access your portfolio
